Ionis Pharmaceuticals Announces Topline Results from Phase 2 Celia Study of Diranersen
Ionis Pharmaceuticals Inc IONS
$74.23
▼ -1.92%
($-1.45)
Open
$75.89
Prev Close
$75.68
Day Range
$73.32 – $75.93
52W Range
$32.00 – $86.74
Market Cap
$12.27B
Beta
0.36
EPS (TTM)
$-2.10
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1991-05-17 |
| Shares Out. | 165,190,000 |
| Website | ionis.com/ ↗ |
| Phone | 17609319200 |
Ionis Pharmaceuticals Inc is a publicly traded company under the ticker symbol IONS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
31 analysts (2026-05-01)
📰 Latest News for IONS
Why Is Biogen Stock Falling Thursday?
Ionis partner Biogen announces topline results from phase 2 Celia study of diranersen
Biogen's Topline Data From Phase 2 CELIA Study Of Diranersen (BIIB080) For Early Alzheimer's Disease Shows Reductions In Tau Pathology
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Transcript : Ionis Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 10
GSK Targets China's Hepatitis B Market Through New Deal